Lipopolysaccharide enhances oxidative modification of low density lipoprotein by copper ions, endothelial and smooth muscle cells

Atherosclerosis

Volumn 143, Issue 1, 1999, Pages 75-80

  Maziere, Cécile ^a   Conte, Marie Alix ^a   Dantin, Françoise ^a   Maziere, Jean Claude ^a  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

Atherosclerosis; Endothelial cells; LDL peroxidation; Lipopolysaccharide (endotoxin); Smooth muscle cells

Indexed keywords

COPPER ION; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; IODINE 125; LOW DENSITY LIPOPROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; ENDOTHELIUM CELL; LIPID PEROXIDATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

CELLS, CULTURED; COPPER; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENDOTOXINS; ESCHERICHIA COLI; LIPOPOLYSACCHARIDES; LIPOPROTEINS, LDL; MACROPHAGES; MUSCLE, SMOOTH, VASCULAR; OXIDATION-REDUCTION; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 0033033390     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00277-9     Document Type: Article

References (39)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the nineties. Nature. 362:1993;801-809.
2. Gerrity R.G. The role of the monocyte in atherogenesis I: transition of blood-born monocytes into foam cells in fatty lesions. Am. J. Pathol. 103:1981;181-190.
3. Steinbrecher U.P., Zhang H., Lougheed M. Role of oxidatively modified LDL in atherosclerosis. Free Rad. Biol. Med. 9:1990;155-168.
4. Steinbrecher U.P., Parthasarathy S., Leake D.S., Witztum J.L., Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. USA. 81:1984;3883-3887.
5. Cathcart M.K., Morel D.W., Chisolm G.M. Monocytes and neutrophils oxidize low density lipoproteins making it cytotoxic. J. Leukoc. Biol. 38:1985;341-350.
6. Henriksen T., Mahoney E.M., Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by the receptor for acetylated low density lipoproteins. Proc. Natl. Acad. Sci. USA. 78:1981;6499-6503.
7. Morel D.W., DiCorleto P.E., Chisolm G.M. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Artherosclerosis. 4:1984;357-364.
8. Esterbauer H., Rotheneder M.D., Waeg G., Striegl G., Jürgens G. Biochemical, structural and functional properties of oxidized low density lipoprotein. Chem. Res. Toxicol. 3:1990;77-92.
9. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherosclerosis. J. Clin. Invest. 88:1991;1785-1792.
10. Yla-Herttuala S. Macrophages and low density lipoprotein in the pathogenesis of atherosclerosis. Ann. Med. 23:1991;561-567.
11. Cathcart M.K., Mc Nally A.K., Morel D.W., Chisolm D.W. Superoxide anion participation in human monocyte-mediated oxidation and conversion of low density lipoprotein to a cytotoxin. J. Immunol. 142:1989;1963-1969.
12. Quinn M.T., Parthasarathy S., Steinberg D. Lysophosphaidyl-choline: a chemotactic factor for human monocytes and its potential role in atherosclerosis. Proc. Natl. Acad. Sci. USA. 85:1988;2805-2809.
13. Cushing S.D., Berliner J.A., Valente A.J. Minimally modified LDL induces monocyte chemotactic proteins 1 in human endothelial and smooth muscle cells. Proc. Natl. Acad. Sci. USA. 87:1990;5134-5138.
14. Drake T.A., Hannani K., Fei H., Lavi S., Berliner J.A. Minimally-oxidized low density lipoprotein induces tissue factor expression in cultured human endothelial cells. Am. J. Pathol. 138:1991;601-607.
15. Woods J.D., Nimmo M.J., Mackay-Scollay E.M. Acute transmural myocardial infarction associated with active Coxsackie virus B infection. Am. Heart J. 89:1975;283-287.
16. Syrijänen J., Valtonen V.V., Livanainen M., Kaste M., Huttunen J.K. Preceding infection as an important risk factor for iscaemic brain infarction in young and middle aged patients. Br. Med. J. 296:1988;1156-1160.
17. Van Lenten B.J., Fogelman A.M., Haberland M.E., Edwards P.A. The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. Proc. Natl. Acad. Sci. USA. 83:1986;2704-2708.
18. Navab M., Hough G.P., Van Lenten B.J., Berliner J.A., Fogelman A.M. Low density lipoproteins transfer bacterial lipopolysaccharides across endothelial monolayers in a biologically active form. J. Clin. Invest. 81:1988;601-605.
19. Reidy M.A., Bowyer D.E. Scanning electron microscopy-morphology of aortic endothelium following injury by endotoxin and during subsequent repair. Atherosclerosis. 26:1977;319-327.
20. Reidy M.A., Bowyer D.E. Distorsion of endothelial repair. The effect of hypercholesterolemia on regeneration of aortic endothelium following injury by endotoxin. Atheroclerosis. 29:1978;459-466.
21. Lopez-Virella M.F. Interactions between bacterial lipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease. Eur. Heart. J. 14:1993;118-124.
22. Havel R.J., Eden M.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34:1955;1345-1353.
23. Bilheimer D.N., Eisenberg S., Levy R.I. The metabolism of very low density lipoproteins. Preliminary in vivo and in vitro observations. Biochem. Biophys. Acta. 260:1972;212-221.
24. Yagi K. Lipid peroxide and human diseases. Chem. Phys. Lipids. 45:1987;337-351.
25. Goldstein J.L., Brown M.S. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J. Biol. Chem. 249:1974;5153-5162.
26. Ulevitch R.J. Recognition of bacterial endotoxins by receptor-dependent mechanisms. Adv. Immunol. 53:1993;267-289.
27. Levine D.M., Parker T.S., Donnelly T.M., Walsh A., Rubin A.L. In vivo protection against endotoxin by plasma high density lipoprotein. Proc. Natl. Acad. Sci. USA. 90:1993;12040-12044.
28. Heinecke W., Baker L., Rosen H., Chait A. Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells. J. Clin. Invest. 77:1986;757-761.
29. Garner B., Dean R.T., Jessup W. Human macrophage-mediated oxidation of low density lipoprotein is delayed and independent of superoxide production. Biochem. J. 301:1994;421-428.
30. Frey-Fressart V., Bonnefont-Rousselot D., Gardes-Albert M. et al. Hydroxyl radical attack of low density lipoprotein decreases its cellular catabolism in the absence of significant lipid peroxidation. Biochem. Biophys. Res. Commun. 208:1995;597-602.
31. Hara-Kuge S., Amano F., Nishijima M., Akamatsu Y. Isolation of a lipopolysaccharide-resistant mutant, with defective LPS binding, of cultured macrophage-like cells. J. Biol. Chem. 265:1990;6606-6610.
32. Feng L., Xia Y., Garcia G.E., Hwang D., Wilson C.B. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin 1, tumor necrosis factor and lipopolysaccharide. J. Clin. Invest. 95:1995;1669-1675.
33. Liu P., Mc Guire G.M., Fischer M.A., Farwood A., Smith C.W., Jaeschke H. Activation of Kupffer cells and neutrophiles for reactive oxygen formation is responsible for endotoxin-enhanced liver injury after hepatic ischemia. Shock. 3:1995;56-62.
34. Geng Y., Zhang B., Lotz M. Protein kinase activation is required for LPS induction of cytokines in human blood monocytes. J. Immunol. 151:1993;6692-6700.
35. Mazière C., Auclair M., Mazière J.C. Tumor necrosis factor enhances low density lipoprotein oxidative modification by monocytes and endothelial cells. FEBS Lett. 338:1994;43-46.
36. Kerttula Y., Weber T.H. Serum lipids in viral and bacterial meningitis. Scand. J. Infect. Dis. 18:1986;211-215.
37. Cabana V.G., Siegel J.W., Sabesin S.M. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J. Lipid Res. 30:1989;39-49.
38. Akerlund B., Carlson L.A., Jarstrand C. Dyslipoproteinemia in patients with severe bacterial infections. Scand. J. Infec. Dis. 18:1986;539-545.
39. Saikku P., Leinonen M., Tenkanen L. et al. Chronic Chlamydia pneumoniae infection as risk factor for coronary heart disease in the Helsinki heart study. Ann. Int. Med. 116:1992;273-278.